InsiderTrades.com logo
Daniel Faga net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Daniel Faga Biography and Net Worth

President & CEO of AnaptysBio

Dan has more than 20 years of operating and advisory experience in the life sciences industry. He has served as Anaptys’ president and chief executive officer since March 2022. Previously, he was chief operating officer at Mirati Therapeutics responsible for leading the company’s corporate strategy, finance, legal and other business operations. Prior to Mirati, Dan was chief business officer at Spark Therapeutics until its acquisition by Roche. Previously, Dan was a managing director and founding member of Centerview Partner’s healthcare advisory practice. Dan’s earlier experience includes healthcare investment banking at Merrill Lynch and management consulting in the life sciences practice at PRTM. Dan earned a B.S. in engineering from Cornell University and an MBA in healthcare management from the Wharton School of the University of Pennsylvania.

What is Daniel Faga's net worth?

The estimated net worth of Daniel Faga is at least $15.31 million as of March 25th, 2024. Mr. Faga owns 749,087 shares of AnaptysBio stock worth more than $15,311,338 as of May 25th. This net worth estimate does not reflect any other assets that Mr. Faga may own. Additionally, Mr. Faga receives a salary of $867,120.00 as President & CEO at AnaptysBio. Learn More about Daniel Faga's net worth.

How old is Daniel Faga?

Mr. Faga is currently 44 years old. There are 5 older executives and no younger executives at AnaptysBio. Learn More on Daniel Faga's age.

What is Daniel Faga's salary?

As the President & CEO of AnaptysBio, Inc., Mr. Faga earns $867,120.00 per year. Learn More on Daniel Faga's salary.

How do I contact Daniel Faga?

The corporate mailing address for Mr. Faga and other AnaptysBio executives is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. AnaptysBio can also be reached via phone at (858) 362-6295 and via email at investors@anaptysbio.com. Learn More on Daniel Faga's contact information.

Has Daniel Faga been buying or selling shares of AnaptysBio?

Daniel Faga has not been actively trading shares of AnaptysBio over the course of the past ninety days. Most recently, Daniel Faga sold 3,000 shares of the business's stock in a transaction on Monday, March 25th. The shares were sold at an average price of $21.42, for a transaction totalling $64,260.00. Following the completion of the sale, the chief executive officer now directly owns 749,087 shares of the company's stock, valued at $16,045,443.54. Learn More on Daniel Faga's trading history.

Who are AnaptysBio's active insiders?

AnaptysBio's insider roster includes Daniel Faga (President & CEO), Dennis Fenton (Director), Paul Lizzul (Chief Medical Officer), Eric Loumeau (COO), Dennis Mulroy (CFO), Hollings Renton (Director), and Hamza Suria (CEO). Learn More on AnaptysBio's active insiders.

Are insiders buying or selling shares of AnaptysBio?

In the last twelve months, AnaptysBio insiders bought shares 3 times. They purchased a total of 345,802 shares worth more than $10,928,220.98. In the last twelve months, insiders at the biotechnology company sold shares 7 times. They sold a total of 37,840 shares worth more than $1,342,179.10. The most recent insider tranaction occured on January, 2nd when Director Ecor1 Capital, Llc bought 6,646 shares worth more than $86,065.70. Insiders at AnaptysBio own 33.5% of the company. Learn More about insider trades at AnaptysBio.

Information on this page was last updated on 1/2/2025.

Daniel Faga Insider Trading History at AnaptysBio

See Full Table

Daniel Faga Buying and Selling Activity at AnaptysBio

This chart shows Daniel Faga's buying and selling at AnaptysBio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$2M$0$2MTotal Insider BuyingTotal Insider Selling

AnaptysBio Company Overview

AnaptysBio logo
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Read More

Today's Range

Now: $20.44
Low: $20.03
High: $20.75

50 Day Range

MA: $19.36
Low: $16.24
High: $22.22

2 Week Range

Now: $20.44
Low: $12.21
High: $41.31

Volume

357,651 shs

Average Volume

602,268 shs

Market Capitalization

$600.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A